JNJJanssen Research & Development, LLCSigning up patients
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 800 (planned)
- Started
- Dec 19, 2025
- Main results expected
- Nov 19, 2027
- Fully finished
- Jun 7, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 1 years 10 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07225946 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC